Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe for prevention of contrast-induced nephropathy
IRCT20250702066339N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ezetimibe in contrast-induced nephropathy (CIN), sponsored by Islamic Azad University. Started Jul 2025; status: completed.
02
Drugs
ezetimibe
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20250702066339N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250702066339N1.